Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Supernus Pharmaceuticals (SUPN) reported $165.45 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 1.7%. EPS of $0.91 for the same period compares to $0.36 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $154.14 million, representing a surprise of +7.34%. The company delivered an EPS surprise of +93.62%, with the consensus EPS estimate being $0.47.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Supernus performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Net product sales- Trokendi XR: $11.2 million versus the three-analyst average estimate of $9.74 million. The reported number represents a year-over-year change of -34.5%.
• Revenues- Net product sales- Oxtellar XR: $11.6 million versus $8.43 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -60.7% change.
• Revenues- Net product sales- Qelbree: $77.6 million versus $71.25 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +30.6% change.
• Revenues- Net product sales: $158 million versus the three-analyst average estimate of $148.32 million. The reported number represents a year-over-year change of -2.8%.
• Revenues- Royalty revenues: $7.46 million versus $5.33 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +28.6% change.
• Revenues- Net product sales- GOCOVRI: $36.7 million versus $33.51 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +15.8% change.
• Revenues- Net product sales- Other: $6.5 million versus $8.21 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -13.3% change.
• Revenues- Net product sales- APOKYN: $12.8 million versus the two-analyst average estimate of $15.6 million. The reported number represents a year-over-year change of -26%.

View all Key Company Metrics for Supernus here>>>

Shares of Supernus have returned +17.8% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Supernus Pharmaceuticals, Inc. (SUPN): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research